Pascal Biosciences Inc (NEVI) AI Stock Analysis

6 Followers

Pascal Biosciences Inc

(CNQX:NEVI)

Select Model

Rating:41Neutral

Price Target:CAD 0.02▲(20.00% Upside)

Action:upgraded

Date:09/07/26

Persistent losses and weak profitability in financials are the primary drags, reinforced by bearish technical signals and unfavorable valuation metrics.

Positive Factors

Manageable LeverageModerate leverage and positive equity provide a stronger financial foundation than the company had in earlier periods. This reduces balance-sheet strain, preserves flexibility for operations, and gives management more capacity to address losses without relying entirely on additional borrowing.

Negative Factors

Sharp Revenue ContractionA sharply contracting top line weakens the company’s ability to absorb fixed operating costs and sustain investment in its business. Persistent revenue pressure would limit the benefit of margin improvements, reduce operating leverage, and make a durable path to profitability more difficult.

Pascal Biosciences Inc (NEVI) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 793.25K
Dividend Yield: ―
Average Volume (3M): 38.07K
Price to Earnings (P/E): -3.0
Beta (1Y): 1.27
Revenue Growth: 9.40%
EPS Growth: 25.81%
Country: Canada
Employees: 2
Sector: Consumer Defensive
Sector Strength: 62
Industry: Beverages - Non-Alcoholic

Pascal Biosciences Inc Business Overview & Revenue Model

Company Description

Nevis Brands Inc. engages in the development and sale of cannabis products in the United States. It offers hemp derived THC beverages under the Major brand name. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis...

Pascal Biosciences Inc Financial Statement Overview

Summary

Revenue growth to $1.7M is positive with cash flow turning positive, but persistent net losses, negative margins, and declining equity indicate ongoing profitability challenges.

Income Statement

35Negative

Balance Sheet

40Negative

Cash Flow

55Neutral

Financial statement breakdown
Breakdown	TTM	Nov 2025	Feb 2025	Feb 2024	Nov 2022	Feb 2022
Income Statement
Total Revenue	1.66M	1.70M	1.55M	671.54K	0	0
Gross Profit	622.70K	396.31K	1.08M	392.94K	-8,294	-16.32K
EBITDA	-32.62K	-32.66K	-48.07K	-271.56K	-468.09K	-1.07M
Net Income	-348.97K	-275.07K	-362.48K	-399.77K	-480.28K	-1.09M
Balance Sheet
Total Assets	1.49M	1.72M	2.04M	2.50M	18.82K	155.19K
Cash, Cash Equivalents and Short-Term Investments	60.85K	102.17K	129.54K	418.52K	8,370	0
Total Debt	394.63K	244.21K	528.30K	683.27K	224.62K	7,759
Total Liabilities	621.16K	746.36K	813.50K	1.12M	962.93K	646.48K
Stockholders Equity	872.36K	968.95K	1.23M	1.38M	-944.11K	-491.30K
Cash Flow
Free Cash Flow	93.88K	62.10K	-132.06K	-390.49K	-147.68K	-614.93K
Operating Cash Flow	93.88K	62.10K	-120.50K	-385.35K	-147.68K	-614.93K
Investing Cash Flow	0	0	-11.56K	-947.71K	8,976	0
Financing Cash Flow	-89.94K	-90.20K	-167.65K	1.76M	154.84K	624.08K

Pascal Biosciences Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

TSE:NEVI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
TSE:MEAT	46Neutral	CAD 220.55K	-0.34	30.06%	―	-3.70%	51.27%
TSE:NEVI	41Neutral	CAD 793.25K	-3.04	-26.77%	―	9.40%	25.81%
TSE:LFST	39Underperform	CAD 1.89M	11.90	0.38%	―	-87.74%	-220.61%

* Consumer Defensive Sector Average

Performance Comparison

TSE:NEVI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:NEVI	Pascal Biosciences Inc	0.02	-0.04	-66.67%
TSE:TAAT	Taat Global Alternatives Inc.	0.17	0.00	0.00%
TSE:MEAT	Modern Plant Based Foods Inc.	0.03	-0.16	-84.21%
TSE:LFST	Lifeist Wellness Inc	0.05	-0.01	-16.67%
TSE:MUSL	Element Nutritional Sciences Inc	0.02	-0.03	-60.00%

Pascal Biosciences Inc Corporate Events

Business Operations and StrategyShareholder Meetings

Nevis Brands Secures Shareholder Backing at 2026 AGM as Cannabis Beverage Expansion Continues

Positive

Sep 25, 2026

Nevis Brands Inc. reported that all resolutions were approved at its 2026 annual general meeting held in Vancouver, with 6,175,076 common shares represented, equal to about 15.57% of shares outstanding. Shareholders confirmed a four-member board, re-...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 07, 2026

Pascal Biosciences Inc AI Stock Analysis